Join our daily newsletter At The Bell to receive exclusive market insights
- Kazia Therapeutics (KZA) is granted patents for the manufacture of Paxalisib by agencies in the US and India
- The original patents for Paxalisib protect its chemical structure, while the new manufacturing patents cover the process by which Paxalisib is made
- The new patents will expire in 2036, but are likely to be eligible for a five-year patent term extension
- Kazia Therapeutics is up 2.31 per cent, trading at $1.33 per share at 1:36 pm AEST
Kazia Therapeutics (KZA) has been granted patents for the manufacture of Paxalisib by agencies in the US and India.
Paxalisib is a brain-penetrant inhibitor which is being developed to treat glioblastoma, the most common and agressive form of primary brain cancer in adults.
The original patents for Paxalisib protect its chemical structure. The newly granted manufacturing patents provide an additional layer of protection for the company by covering the process by which Paxalisib is made. This means competitors would need to develop an alternative method of chemical synthesis to create the treatment, which is said to be challenging and costly.
The new patents will expire in 2036, but are likely to be eligible for a five-year patent term extension.
A similar patent has already been accepted in Australia and is expected to proceed to grant in the third quarter of 2021.
Kazia CEO James Garner said: “As we move towards commercialisation, we have worked closely with our IP counsel to ensure we achieve the maximum possible degree and duration of protection for the intellectual property embodied in Paxalisib.”
Further patents still remain pending in Europe, China, Canada and other territories, which the company expects to be approved in due course.
Kazia Therapeutics was up 2.31 per cent, trading at $1.33 per share at 1:36 pm AEST.
